166545 Role of the Synar amendment in efforts to prevent tobacco addiction

Tuesday, November 6, 2007: 9:05 AM

Jennifer L. Wagner , SPFAS Project, JBS International, Inc., Silver Spring, MD
Background: Tobacco addiction is the single most preventable cause of death and disease in our society. One method to reduce the prevalence of tobacco addiction is to stop the sale of tobacco to minors. The Center for Substance Abuse Prevention (CSAP) has supported State efforts to control youth access to tobacco products through the Synar Amendment for the last 10 years through the requirement of random inspections of tobacco retailers. Methods: In 1996, CSAP began requiring that States use a probability sample to conduct inspections. The Synar Amendment requires that States: (1) have a law prohibiting the sale of tobacco products to minors, (2) enforce such laws in a manner that can reasonably reduce the extent to which tobacco products are available to youth, and (3) conduct annual, random, unannounced inspections to ensure compliance with the law. CSAP has monitored and supported all 59 States and territories in their efforts to comply with these requirements. Results: Between 1997 and 2006, the national retailer violation rate has dropped 30 percentage points, from 40.1% in 1997 to 10.9% in 2006. The 2006 National Synar Rates will be released by SAMHSA/CSAP Summer 2007. Discussion: According to the National Survey on Drug Use and Health, the rate of cigarette use in youth age 12–17 has begun to decline (13.0% in 2002 to 10.8% in 2005). Environmental strategies such as the Synar Amendment have contributed to this decline and may continue to be an effective tool in our efforts to curb tobacco addiction.

Learning Objectives:
1. Describe the Synar program and its requirements 2. Discuss the Synar program's contribution to tobacco prevention efforts and the reduction in tobacco use.

Keywords: Tobacco Control, Tobacco Policy

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

See more of: Late Breaking Policy Issues
See more of: Epidemiology